Dataset Information

Genetics of symptom remission in outpatients with COVID-19.

ABSTRACT: We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; P = 4.94 × 10^-8) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. In 851 participants not treated with colchicine (placebo), there was a significant association at 9q33.1 (rs62575331; P = 2.95 × 10^-8) in interaction with colchicine (P = 1.19 × 10^-5) without impact on risk of hospitalisations, highlighting a possibly shared mechanistic pathway. By day 15 of the study, 46%, 62% and 64% of those with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. The findings need to be replicated and could contribute to the biological understanding of COVID-19 symptom remission.

SUBMITTER: Dube MP

PROVIDER: S-EPMC8149390 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Genetics of symptom remission in outpatients with COVID-19.

Dubé Marie-Pierre MP Lemaçon Audrey A Barhdadi Amina A Lemieux Perreault Louis-Philippe LP Oussaïd Essaïd E Asselin Géraldine G Provost Sylvie S Sun Maxine M Sandoval Johanna J Legault Marc-André MA Mongrain Ian I Dubois Anick A Valois Diane D Dedelis Emma E Lousky Jennifer J Choi Julie J Goulet Elisabeth E Savard Christiane C Chicoine Lea-Mei LM Cossette Mariève M Chabot-Blanchet Malorie M Guertin Marie-Claude MC de Denus Simon S Bouabdallaoui Nadia N Marchand Richard R Bassevitch Zohar Z Nozza Anna A Gaudet Daniel D L'Allier Philippe L PL Hussin Julie J Boivin Guy G Busseuil David D Tardif Jean-Claude JC

Scientific reports 20210525 1

We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; P = 4.94 × 10<sup>-8</sup>) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. In 851 participants not treated ...[more]

PMID: 34035401

Similar Datasets

Project description:IntroductionWith the emergence of new SARS-CoV-2 variants has come significant variations in disease manifestation, severity, and duration in non-hospitalized infected patients. To characterize symptom patterns and risk factors associated with symptom severity and duration, COVID-19 and influenza-like illness (ILI) outpatients and their contacts were enrolled at two sites in the United States of America and one site in Thailand.MethodsCOVID-19 infection was confirmed at enrollment with a positive antigen or PCR test. Baseline demographics and medical histories were collected from participants at enrollment and daily self-reported symptom questionnaires were obtained to assess symptom severity and duration. Risk factors associated with symptom severity and duration were determined by multivariate logistic regression and Cox proportional hazards model.ResultsTwo hundred and forty one participants meeting the eligibility criteria were enrolled, including 174 confirmed COVID-19 cases (9% Delta and 90% Omicron), 33 ILI cases, and 34 healthy contacts. COVID-19 participants had a shorter median symptom duration of 9.0 (95% CI, 8.0-11.0) days than ILI participants. Infection with the Delta variant resulted in a longer symptom alleviation period compared to infection with the Omicron variant. The most commonly reported symptoms among COVID-19 participants were reported in the nasal and chest/respiratory domains of the FLU-PRO Plus. Participants infected with the Delta variant reported more symptoms overall, with significantly more symptoms affecting eyes and senses reported. 55% of SARS-CoV-2-positive participants reached a negative N1 Ct value by the day 14 study time point. No risk factors for moderate to severe symptoms were identified in this outpatient cohort. Male sex was associated with a shorter symptom duration.ConclusionSymptom manifestation varied among Delta and Omicron variants. Few risk factors were identified for increased symptom severity or duration.

Dataset Information

Genetics of symptom remission in outpatients with COVID-19.

Publications

Genetics of symptom remission in outpatients with COVID-19.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets